5-phenoxypentan-1-ol | 16654-52-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-phenoxypentan-1-ol
• 英文别名: 5-Phenoxy-pentanol-(1)；5-phenoxy-1-pentanol；α-oxy-ε-phenoxy-pentane；Pentamethylenglykol-monophenylaether；α-Oxy-ε-phenoxy-pentan
• CAS: 16654-52-7
• 化学式: C₁₁H₁₆O₂
• 分子量: 180.247
• InChiKey: CDRCNCMLLKIQNT-UHFFFAOYSA-N

物化性质

• 沸点：
  150-155 °C(Press: 11 Torr)
• 密度：
  1.018±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-phenoxypentan-1-ol 在 乙醇 、 sodium ethanolate 、 三溴化磷 作用下， 生成 ethyl 7-(phenoxy)heptanoate
  参考文献：
  名称：

  CYCLIC QUATERNARY AMMONIUM SALTS FROM HALOGENATED ALIPHATIC TERTIARY AMINES

  摘要：

  DOI：

  10.1021/ja01364a041
• 作为产物：
  描述：

  4-苯氧基丁基溴 在 lithium aluminium tetrahydride 作用下， 生成 5-phenoxypentan-1-ol
  参考文献：
  名称：

  Mass spectrometry in structural and stereochemical problems. CLV. Electron impact induced fragmentations and rearrangements of some trimethylsilyl ethers of aliphatic glycols, and related compounds

  摘要：

  DOI：

  10.1021/jo01270a022

文献信息

• Copper(II)-Catalyzed Monoarylation of Vicinal Diols with Diaryliodonium Salts
  作者：Masami Kuriyama、Norihisa Hamaguchi、Osamu Onomura

  DOI：10.1002/chem.201102770

  日期：2012.2.6

  Selective and efficient: The copper(II)‐catalyzed selective monoarylation of vicinal diols with diaryliodonium triflates was successfully developed. In this catalytic process high chemoselectivity was achieved, even in the presence of a 1:1 mixture of the 1,2‐diol and the mono‐ol, and a wide range of substrates was tolerated, giving the monoarylated products in good to excellent yields (see scheme)

  选择性和高效：成功开发了铜（II）催化邻二元二醇与二芳基碘鎓三氟甲磺酸酯的选择性单芳基化反应。在这种催化过程中，即使存在1,2-二醇和一元醇的1：1混合物，也能实现高化学选择性，并且可以耐受多种底物，从而使单芳基化产物的收率良好至优异（请参阅方案）。
• Novel compounds and their use
  申请人：——

  公开号：US20020147200A1

  公开（公告）日：2002-10-10

  A compound of the general formula (I): 1 wherein R 1 , R 2 , X, Y and Z are as described in the specification.

  通式（I）的化合物：其中R1、R2、X、Y和Z如规范中所述。
• [EN] CARBOSTYRIL COMPOUND<br/>[FR] DÉRIVÉ DE CARBOSTYRILE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2006035954A1

  公开（公告）日：2006-04-06

  The present invention provides a carbostyril compound represented by General Formula (1) or a salt thereof, wherein A is a direct bond, a lower alkylene group, or a lower alkylidene group; X is an oxygen atom or a sulfur atom; R4 and R5 each represent a hydrogen atom; the bond between the 3 and 4 positions of the carbostyril skeleton is a single bond or a double bond; R1 is a hydrogen atom, etc; R2 is a hydrogen atom, etc; and R3 is a hydrogen atom, etc. The carbostyril compound or salt thereof of the present invention induces the production of TFF, and thus is usable for the treatment and/or prevention of disorders such as alimentary tract diseases, oral diseases, upper respiratory tract diseases, respiratory tract diseases, eye diseases, cancers, and wounds.

  本发明提供了一种由通式（1）表示的羧基吲哚化合物或其盐，其中A是直链键、较低的烷基烯基或较低的烷基亚烯基；X是氧原子或硫原子；R4和R5分别表示氢原子；羧基吲哚骨架的3和4位置之间的键是单键或双键；R1是氢原子，等等；R2是氢原子，等等；R3是氢原子，等等。本发明的羧基吲哚化合物或其盐诱导TFF的产生，因此可用于治疗和/或预防消化道疾病、口腔疾病、上呼吸道疾病、呼吸道疾病、眼部疾病、癌症和伤口等疾病。
• Synthesis of phosphodiester-type nicotinamide adenine dinucleotide analogs
  作者：Wujun Liu、Siguo Wu、Shuhua Hou、Zongbao (Kent) Zhao

  DOI：10.1016/j.tet.2009.08.007

  日期：2009.10

  Fourteen phosphodiester-type β-nicotinamide adenine dinucleotide (NAD+) analogs were prepared starting from nicotinamide. The phosphodiester linkage was effectively assembled in 69–93% yields via condensation reaction between 2′,3′-di-O-acetyl nicotinamide mononucleotide and alcohols in the presence of 2,4,6-triisopropylbenzenesulfonyl chloride. The analog β-nicotinamide ribose-5-(2-phenylethyl) phosphate

  从烟酰胺开始制备了十四种磷酸二酯型β-烟酰胺腺嘌呤二核苷酸（NAD +）类似物。在2,4,6-三异丙基苯磺酰氯存在下，通过2'，3'-二-O-乙酰基烟酰胺单核苷酸与醇之间的缩合反应，磷酸二酯键的组装效率为69-93％。模拟的β-烟酰胺核糖-5-（2-苯基乙基）磷酸酯对模型微生物的细胞生长显示出有益的作用。
• Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
  申请人：——

  公开号：US20030139431A1

  公开（公告）日：2003-07-24

  This invention provides compounds having the structure: 1 wherein X=CH, C(CH 3 ) or N; each of R 1 , R 2 , R 3 , R 4 and R 5 is independently H, C 1 -C 10 straight chained or branched alkyl, C 2 -C 10 straight chained or branched alkenyl, C 2 -C 10 straight chained or branched alkynyl, C 3 -C 10 cycloalkyl, substituted or unsubstituted aryl, hydroxy, halogenated ether, nitro, amino, halogen, —CN, —C(═Z)R 6 , —C(═Z)OR 6 , —C(═Z)N(R 6 ) 2 , —N(R 6 )—C(═Z)R 6 , —N(R 6 )—C(═Z)N(R 6 ) 2 , —OC(═Z)R 6 , —C(═Z)OR 6 —OR 6 or —SR 6 ; wherein Z is O or S; and wherein R 6 is C 1 -C 10 straight chained or branched alkyl, aryl, (CH 2 ) n Q, C 2 -C 10 alkenyl, C 3 -C 10 cycloalkyl, C 5 -C 10 cycloalkenyl, wherein Q is OR 7 , SR 7 , N(R 7 ) 2 or aryl, wherein R 7 is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, wherein R 2 and R 3 and the carbons to which they are attached form a fused aryl, heteroaryl, C 5 -C 10 cyclic alkyl or heterocyclic alkyl ring; or wherein R 3 and R 4 and the carbons to which they are attached form a fused aryl, heteroaryl, cyclic alkyl or heterocyclic alkyl ring; and wherein each alkyl, alkenyl, alkynyl and alkoxy group is optionally substituted with a substituent independently selected from R a , where R a is 1) hydroxy, 2) C 1 -C 10 alkoxy, 3) halogen, 4) nitro, 5) amino, 6) CF 3 , or 7) carboxy, and each cycloalkyl group is optionally substituted with a substituent independently selected from R b , where R b is 1) a group selected from R a , 2) C 1 -C 7 alkyl, 3) C 2 -C 7 alkenyl, 4) C 2 -C 7 alkynyl or 5) cyclic C 1 -C 10 alkyl, and each aryl is optionally substituted with R 1 . This invention also provides methods of treating pain, urge incontinence; as well as methods of preparing the compounds.

  这项发明提供了具有以下结构的化合物：其中 X==CH，C(CH3)或N；R1、R2、R3、R4和R5中的每一个独立地是H、C1-C10直链或支链烷基、C2-C10直链或支链烯基、C2-C10直链或支链炔基、C3-C10环烷基、取代或未取代芳基、羟基、卤代醚、硝基、氨基、卤素、—CN、—C(═Z)R6、—C(═Z)OR6、—C(═Z)N(R6)2、—N(R6)—C(═Z)R6、—N(R6)—C(═Z)N(R6)2、—OC(═Z)R6、—C(═Z)OR6—OR6或—SR6；其中 Z 是 O 或 S；且其中 R6 是 C1-C10直链或支链烷基、芳基、(CH2)nQ、C2-C10烯基、C3-C10环烷基、C5-C10环烯基，其中 Q 是OR7、SR7、N(R7)2或芳基，其中 R7 是H、烷基、烯基、炔基、环烷基、环烯基、芳基，其中 R2、R3和它们连接的碳形成融合芳基、杂芳基、C5-C10环烷基或杂环烷基环；或其中 R3、R4和它们连接的碳形成融合芳基、杂芳基、环烷基或杂环烷基环；以及每个烷基、烯基、炔基和烷氧基组分可以选择性地取代一个从 Ra 中独立选择的取代基，其中 Ra 是 1) 羟基，2) C1-C10烷氧基，3) 卤素，4) 硝基，5) 氨基，6) CF3，或 7) 羧基，每个环烷基组分可以选择性地取代一个从 Rb 中独立选择的取代基，其中 Rb 是 1) 从 Ra 中选择的一组，2) C1-C7烷基，3) C2-C7烯基，4) C2-C7炔基或 5) 环状 C1-C10 烷基，每个芳基可以选择性地取代为 R1。这项发明还提供了治疗疼痛、尿急失禁的方法；以及制备这些化合物的方法。